In this week's Targeted Pulse, we cover new FDA designations for cancer drugs, advances in targeted therapies, and key ...

The regulatory actions were based on results from the Phase III MATTERHORN trial (NCT04592913), which showed that a ...

Nurses at Katz Women’s Hospital had to complete comprehensive education requirements for the hospital to obtain the ...

Silverberg, J.I., Rosmarin, D., Chovatiya, R. et al. The regulatory T cell-selective interleukin-2 receptor agonist ...

Calidi Biotherapeutics, Inc. ('Calidi” or the 'Company”) (NYSE American: CLDI), a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver ...

Creditors navigating the challenges of Subchapter V bankruptcy proceedings must understand their rights, strategies for ...

Flexible spending accounts are offered by employers, and contributions are limited annually (in 2025, the limit is $3,300).

The Food and Drug Administration has granted Fast Track designation to PMN310 for the treatment of Alzheimer disease.

PM EST Webcast Link: Canaccord Genuity / Candel Presentation A webcast of the presentation will be available by selecting Events and Presentations under the News & Events tab in the Investors section ...

The Midcontinent Independent System Operator overstated the benefits of transmission projects approved in December, according ...

Lawmakers were focused on the state budget the last few weeks but introduced several notable bills in July, including ...

At least 11 children in the U.S. have died from influenza-associated acute necrotizing encephalopathy since October 2023, a ...